Apr 28, 2015 at 11:32 | Source: Reuters
The just completed Ranbaxy deal, its biggest to date at USD 3.2 billion, has given India's biggest drugmaker sufficient scale in generics and emerging markets to think about its next step - beefing up expertise in higher margin products and gaining a bigger global presence.
Apr 28, 2015 at 11:30 | Source: CNBC-TV18
Deepak Shenoy of Capital Mind is of the view that one may prefer Strides Arcolab and Sun Pharma.
Apr 23, 2015 at 14:18 | Source: CNBC-TV18
Jitendra Sriram, MD & Head-Research of HSBC India prefers Infosys and Sun Pharmaceutical Industries.
Apr 22, 2015 at 13:20 | Source: PTI
The company was clarifying on speculations that Sanghvi, who holds 9.61 percent stake in Sun Pharma, had bought shares when Daiichi Sankyo exited from the Indian firm.
Apr 22, 2015 at 12:46 | Source: CNBC-TV18
The pharma space has been in focus post Sun Pharma-Daiichi deal and the likelihood of a possible merger between Teva and Mylan globally. In an interview to CNBC-TV18, Abhishek Sharma of IIFL discusses his outlook on the sector and on specific companies.
Apr 20, 2015 at 20:15 | Source: PTI
As part of the deal, Ranbaxy shareholders were to receive 0.8 Sun Pharma shares for every Ranbaxy share they held. Daiichi Sankyo, which had acquired a majority stake in Ranbaxy in 2008 for around Rs 22,000 crore, held 63.4 percent in the Gurgaon-based firm at the time of the merger.
Apr 20, 2015 at 18:13 | Source: CNBC-TV18
Goldman Sachs is learnt to be the banker to Sun Pharma-Daiichi Sankyo deal.
Apr 10, 2015 at 15:46 | Source: CNBC-TV18
Gaurang Shah of Geojit BNP Paribas Financial Services is of the view that one may hold Reliance Industries with a target Rs 980.
Apr 07, 2015 at 10:57 | Source: CNBC-TV18
Vikas Khemani, President, Co-Head Wholesale Capital Markets at Edelweiss Capital has a positive view on Sun Pharma.
Apr 06, 2015 at 16:28 | Source: CNBC-TV18
Mayuresh Joshi - fund manager - PMS at Angel Broking recommends holding Sun Pharma.